Aktie ARQULE, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen ArQule, Inc.

Aktien

US04269E1073

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
ArQule : Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors
Merck : KEYTRUDA Superior to Brentuximab Vedotin, a Standard of Care, in Patients with Classical Hodgkin Lymphoma in Head-to-Head Phase 3 Trial
ARQULE INC : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
ArQule, Inc. Announces Management Changes
ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P TMI Index
ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P Biotechnology Select Industry Index
ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P Global BMI Index
Merck Sharp & Dohme Corp. completed the acquisition of ArQule, Inc..
ARQULE INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
NASDAQ COMPOSITE : Wall Street finit en baisse à l'approche d'une échéance clé pour le commerce
Fate Therapeutics : ArQule and Fate Therapeutics soar; Sanofi and Diplomat fall
Wall St. falls as Apple, health shares drag, tariff deadline looms
DOW JONES 30 : Wall Street ouvre en légère baisse
ArQule : Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
ArQule, Inc. Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
ARQULE INC : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
USA-Les valeurs à suivre à Wall Street (actualisé)
Merck Sharp & Dohme Corp. entered into a definitive agreement to acquire ArQule, Inc. for $2.4 billion.
ArQule : to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. Aktie
  4. Nachrichten ArQule, Inc.
  5. Andere Sprachen